

Estimation of (IgA) antigliadin, (IgA) antiendomysium and (IgA) tissue transglutaminase in the serum of psoriatic patients

Thesis

**Submitted For fulfillment of M.Sc. Degree
in Dermatology, Andrology and STDs**

By

Dina Fathi EL-Deeb
(M.B.B.Ch.)

Supervised by

Ass. Prof. Dr. Noha Abd EL-Raheem Nagui

**Assistant Professor of Dermatology
Faculty of Medicine – Cairo University**

Dr. Eman Ahmed EL-Nabarawy

**Lecturer of Dermatology
Faculty of Medicine – Cairo University**

Dr. Neveen Ezzat Saad

**Assistant Professor of Chemical and Clinical Pathology
National Research Center**

**Faculty of Medicine
Cairo University**

2009

ACKNOWLEDGMENT

Thanks to God first and foremost. I feel always indebted to God, the most kind and the most merciful.

I would like to express my gratefulness and respect to Prof. Dr. Noha Abd EL Reheem Nagui, Assistant professor of Dermatology, Faculty of Medicine, Cairo University, for her moral and scientific support and for giving me the honor of working under her supervision and valuable guidance.

Special thanks and deepest gratitude to Dr. Eman Ahmed EL Nabarawy, Lecturer of Dermatology, Faculty of Medicine, Cairo University, for her constructive and instructive comments and valuable suggestions. She encouraged me all the time for a better performance. Without her generous help, this work would not have been accomplished in its present picture.

I would like to express my gratitude and appreciation to Dr. Neiveen Ezzat Saad Assistant Professor in Chemical and Clinical Pathology, National Research Center, for her sincere scientific and moral help.

Special thanks to Dr. Iman Shaarawy, Dr. Heba M. meshaly, Dr. Doaa Mahgoub Dr marwa fawzy Julba, for their generous help during work.

My deep thanks are paid to Dr. Mahmoud Fawzy, Abd EL Hamid Lecturer of Dermatology and Venereology, National Research Center, for his valuable advice, support and encouragement.

I am very grateful to all my staff members and my colleagues in the Dermatology Department, Faculty of Medicine, Cairo University and Dermatology and Venereology Research Department, National Research Center, for their help and support throughout the course of the work.

Words can not describe my gratefulness and gratitude to my Husband for his help, Patience and great care and My family as they provided me with every mean of support throughout my life.

LIST OF CONTENTS

PAGE

➤ LIST OF TABLES-----	
➤ LIST OF FIGURES -----	
➤ LIST OF ABBREVIATIONS-----	
➤ INTRODUCTION & AIM OF THE WORK -----	
➤ REVIEW OF LITERATURE-----	

Chapter I

• <i>An overview on psoriasis</i> -----	4
---	----------

Chapter II

• <i>Gluten sensitive enteropathies</i> -----	27
---	-----------

<i>A- Coeliac disease</i> -----	27
---------------------------------	-----------

○ <i>Epidemiology</i> -----	28
○ <i>Pathogenesis</i> -----	30
○ <i>Clinical presentation</i> -----	34
▪ <i>Diagnosis of coeliac disease</i> -----	37
▪ <i>Treatment</i> -----	41
▪ <i>Prognosis</i> -----	44

<i>B-Cutaneous manifestation in coeliac disease</i> -----	45
---	-----------

Chapter III

• <i>Psoriasis and coeliac disease</i> -----	62
--	-----------

○ <i>Special types of psoriasis and coeliac disease</i> -----	66
○ <i>Psoriatic arthritis and coeliac disease</i> -----	71

➤ PATIENTS AND METHODS -----	76
➤ RESULTS -----	89
➤ DISCUSSION -----	109
➤ RECOMMENDATIONS -----	117
➤ SUMMARY -----	118
➤ REFERNCES -----	122
➤ ARABIC SUMMARY -----	

ABSTRACT

Background: *Psoriasis* is a chronic inflammatory skin disease. Genetic and immunologic mechanisms have been proposed in the aetiology of psoriasis. **Coeliac disease (CD)** can be defined as a chronic immune-mediated gluten-dependent enteropathy, resulting from an inappropriate T-cell-mediated immune response against ingested gluten in genetically predisposed people. Recent studies showed an association between CD and psoriasis and an improvement of skin lesions after 3–6 months GFD. Our study was undertaken to assess whether patients with psoriasis in Egypt have an increased prevalence of AGA and other coeliac disease antibodies or not and their possible role in the pathogenesis of psoriasis.

Materials and Methods: This study comprised 41 patients of psoriasis vulgaris and 41 of healthy controls. All cases were subjected to complete history taking, clinical examination including psoriasis area and severity index (PASI) score. Patients and healthy controls were screened for serum IgA antibodies to gliadin (AGA) , IgA antitransglutaminase (TGA) as measured by ELISA and IgA antibodies to endomysium (EMA), assessed by standard immunofluorescence with cryosection of monkey esophagus.

Results Our results showed significant difference between cases and controls as regards IgA (AGA) where as 34.1% of patients had IgA (AGA) positive as compared with controls (2.4%) with significant correlation between IgA (AGA) and duration and course of psoriasis and no significant difference between cases and controls as regards IgA (tTG) where as 34.1% of patients had IgA (tTG) positive as compared with controls (22%). Also we found no significant difference between cases and controls as regards IgA (EMA) where as (14.6%) of patients had IgA (EMA) positive as compared with controls (4.9%).

Conclusion: Our study demonstrated significant increase in levels of CD antibodies in psoriatic patients in comparison to the controls so the serological evaluation for coeliac disease antibodies should be considered in psoriatic patients and early diagnosis of CD and administration of a gluten-free diet could lead to better management of such patients and might also result in decreased morbidity of such chronic skin disease.

Key words: coeliac disease, AGA antibodies, psoriasis.

LIST OF TABLES

Table No.	Description	Page No.
1	Defention of psoriasis severity.	6
2	Potential psoriasis- susceptibility loci.	8
3	Key cytokines produced by T lymphocytes, keratinoyctes, and their known function in psoriasis.	21
4	Risks groups and associated disorders of coeliac disease.	36
5	Clinical data of psoriatic patients.	90
6	Serum level of IgA antigliadin (AGA) in patients and controls.	91
7	Comparison of IgA antigliadin (AGA) serum level in patients and controls.	92
8	Relation of IgA (AGA) serum level to the age of patients and controls.	93
9	Relation of IgA (AGA) serum level to the sex of patients and controls.	93
10	Relation between duration of psoriasis and serum IgA antigliadin (AGA) level.	94
11	Relation of IgA antigliadin (AGA) serum level to the course of psoriasis.	95
12	IgA antigliadin (AGA) serum level in relation to PASI score of psoriasis.	95
13	Relation of IgA (AGA) to family history of psoriasis.	96
14	Relation of IgA (AGA) to the history of food intolerance.	96
15	Serum level of IgA tissue transglutaminase (tTG) in patients and controls.	97
16	Results of comparison of IgA tissue transglutaminase (tTG)	98

	serum level in patients and controls.	
17	Relation of IgA (tTG) serum level to the age of patients and controls	99
18	Relation of IgA (tTG) serum level to the sex of patients and control	99
19	IgA tissue transglutaminase (tTG) serum level in relation to the duration of psoriasis.	100
20	Relation of IgA tissue transglutaminase (tTG) serum level to the course of psoriasis.	100
21	IgA tissue transglutaminase (tTG) serum level in relation to PASI score of psoriasis.	100
22	Relation of IgA (tTG) to family history of psoriasis.	101
23	Relation of IgA (tTG) to history of food intolerance.	102
24	Serum level of IgA Endomysium antibody (EMA) in patients and controls.	103
25	Comparison of IgA Endomysium antibody (EMA) positivity in patients and controls.	104
26	Relation of IgA (EMA) positivity to the age of patients and controls.	105
27	Relation of IgA (EMA) positivity to the sex of patients and controls.	105
28	Relation of IgA Endomysium antibody (EMA) positivity to the duration of psoriasis.	106
29	Relation of IgA Endomysium antibody (EMA) positivity and the course of psoriasis.	106
30	IgA Endomysium antibody (EMA) positivity in relation to PASI score of psoriasis.	107
31	Relation of IgA (EMA) to family history of psoriasis.	107
32	Relation of IgA (EMA) to the history of food intolerance.	108

LIST OF FIGURES

Figure No.	Description	Page No.
1	T-lymphocyte activation by APCs adapted from (Kruger, 2002).	16
2	T-lymphocyte activation by APCs adapted from (Kruger and Ellis, 2005).	18
3	Steps of T-cell migration to the skin modified from (Kruger, 2002).	18
4	Cytokines and adhesion molecules in psoriasis (Kupper, 2003).	22
5	Comparison of IgA antigliadin (AGA) serum level in patients and controls.	92
6	Correlation between IgA (AGA) and duration of psoriasis of patients included in the study.	94
7	Correlation between IgA (AGA) and PASI of patients included in the study.	95
8	Comparison of IgA tissue transglutaminase (tTG) serum level in patients and controls.	98
9	Correlation between IgA (tTG) and PASI of patients included in the study.	101
10	Comparison of IgA Endomysium antibody (EMA) positivity in patients and controls.	104
11	Correlation between IgA (EMA) positivity and PASI of patients included in the study.	107

List of Abbreviations

<i>AA</i>	Arachidonic Acid
<i>AGA</i>	Antigliadin Antibodies
<i>AHL</i>	Acquired Hypertrichosis Lanuginosa
<i>AIDS</i>	Acquired Immune Deficiency Syndrome
<i>APCS</i>	Antigen Presenting Cells
<i>ARA</i>	Antireticulin Antibodies
<i>B.C</i>	Before Christ
<i>BD</i>	Behcets Disease
<i>BMI</i>	Body Mass Index
<i>BSA</i>	Body Surface Area
<i>C3</i>	Complement 3
<i>C5</i>	Complement 5
<i>cAMP</i>	cyclic Adenosine Monophosphate
<i>cGMP</i>	cyclic Guanthine Monophosphate
<i>CD</i>	Coeliac Disease
<i>CL</i>	Cutis Laxa
<i>CLA</i>	Cutaneous Lymphocyte Antigen
<i>CsA</i>	Cyclosporine
<i>DCs</i>	Dendritic cells
<i>DH</i>	Dermatitis Herpetiformis
<i>DIP</i>	Distal Interphalangeal
<i>ECP</i>	Eosinophil Cation Protein
<i>EED</i>	Erythema Elevatum Diminutum
<i>EG2</i>	Eosinophil Granules
<i>EGF</i>	Epidermal Growth Factor
<i>ELISA</i>	Enzyme Linked Immunosorbent Assay
<i>EMA</i>	Endomysial Antibodies
<i>EN</i>	Erythema Nodosum
<i>ESPGAN</i>	European Society For Pediatric Gastroentrology And Nutrition.
<i>ESR</i>	Erythrocyte Sedmintation Rate
<i>FDA</i>	Food and Drug Administration,

<i>G</i>	Group
<i>GACL</i>	Generalized Acquired Cuits Latxa
<i>GERD</i>	Gastero-Esophageal Reflux
<i>GFD</i>	Gluten Free Diet
<i>GI</i>	Gasterointestinal
<i>GSE</i>	Gluten Sensitive Enteropathy
<i>HANE</i>	Hereditary Angioneurotic Oedema
<i>HEVS</i>	High Endothelial Venules
<i>HIV</i>	Human Immunodeficiency Virus
<i>HLA</i>	Human leukocyte Antigen
<i>HSV</i>	Herpes Simplex Virus
<i>IBD</i>	Inflammatory Bowel Disease
<i>IELS</i>	Intraepithelial lymphocytes
<i>IFN-γ</i>	Interferon gamma
<i>IgA</i>	Immunglobulin A
<i>IgG</i>	Immunglobulin G
<i>IgM</i>	Immunglobulin M
<i>IL2</i>	Interleukin 2
<i>IL-2Rα</i>	Interleukin-2 receptor alpha
<i>ILF</i>	Interleukin-enhancer binding Factor
<i>IM</i>	Intramuscular
<i>IV</i>	Intravenous
<i>JDM</i>	Juvenile Dermatomyositis
<i>LABA</i>	Linear IgA Bullous Dermatosi
<i>LC</i>	Langerhans Cell
<i>LT</i>	Leukotrienes
<i>LFA</i>	Lymphocyte Functional Antigen
<i>MHC</i>	Major Histocompatibility Complex
<i>NGF</i>	Nerve Growth Factor
<i>NK</i>	Natural Killer
<i>NME</i>	Necrolytic Migratory Erythema
<i>NPF</i>	National Psoriasis Foundation
<i>NSAIDS</i>	Non Steroidal Anti-Inflammatory Drugs
<i>PASI</i>	Psoriasis Area and Severity Index
<i>PG</i>	Prostaglandin

<i>PM</i>	Pyoderma gangrenosum
<i>PMNs</i>	Polymorph Nuclear Leukocytes
<i>PPP</i>	Palmoplantar Pustulosis
<i>PsA</i>	Psoriatic Arthropathy
<i>PSORS</i>	Psoriasis Susceptibility locus
<i>PsV</i>	Psoriasis Vulgaris
<i>PT</i>	Prothrombin Time
<i>PUFA</i>	Polyunsaturated Fatty Acid
<i>PUVA</i>	Psoralen and Ultraviolet A
<i>QOL</i>	Quality Of Life
<i>RA</i>	Rheumatoid Arthritis
<i>RF</i>	Rheumatoid Factor
<i>SP</i>	Substance P
<i>Tc</i>	Cytotoxic T cell
<i>TCGF</i>	T-Cell Growth Factor
<i>TCR</i>	T Cell Receptor
<i>TgA</i>	Tissue Transglutaminase
<i>TGF</i>	Transforming Growth Factor
<i>Th</i>	Helper T cell
<i>TNF-α</i>	Tumor Necrosis Factor alpha
<i>VCAM</i>	Vascular Cell Adhesion Molecule
<i>VDR</i>	Vitamin D Receptor
<i>VEG-F</i>	Vascular Endothelial Growth Factor
<i>VLA</i>	Very Late Appearing Antigen
<i>VP</i>	Variegate Porphyria

INTRODUCTION & AIM OF THE WORK

Coeliac disease (CD) is an immunomediated enteropathy caused by permanent intolerance to dietary wheat gliadin in predisposed individuals. It is characterized clinically by malabsorption and histologically by villous atrophy and crypt hyperplasia. The true prevalence of CD is difficult to ascertain, and the diagnosis might be delayed because its clinical presentation is often oligosymptomatic. Epidemiological studies in which serological tests have been used show the disease to be much more common than previously realized. Many autoimmune disorders, such as dermatitis herpetiformis, thyroiditis, and diabetes mellitus, are associated with CD (*Ojetti et al., 2003*).

Psoriasis is considered to be a genetically programmed disease of dysregulated inflammation, which is driven and maintained by multiple components of the immune system. The pathologic collaboration between innate immunity (mediated by antigen presenting cells and natural killer T-lymphocytes) and acquired immunity (mediated by T-lymphocytes) results in the production of cytokines, chemokines and growth factors that contribute to the inflammatory infiltrate seen in psoriatic plaques (*Gaspari, 2006*).

Although the exact aetiopathogenesis is unknown, there is growing evidence that activated T cells are the primary modulators in the pathogenesis of psoriasis causing keratinocyte hyperproliferation in the epidermis. This is further supported by the fact that increased levels of activated T lymphocytes are present in psoriatic skin plaques and blood of patients (*Ellis and Krueger, 2001*).

The systemic aspects of psoriasis have been underscored, and among the various factors thought to be involved in the aetiology and pathogenesis, bowel pathology has assumed a noteworthy position in the literature (*Mcmillan et al., 2000*). Previous studies, in fact, showed a high prevalence of IgA antibodies to gliadin (AGA) in patients affected by psoriasis (*Lindquist et al., 2002*) and showed that a gluten-free diet significantly improved the psoriatic lesions (*Michaëlsson et al., 2000*).

It is not easy to explain the possible links between psoriasis and gluten sensitive enteropathy, especially coeliac disease. Keratinocyte hyperproliferation in psoriasis produces a broad spectrum of cytokines, in particular interleukin IL-1 and IL-18 (*Gangemi et al., 2003*). These two potent inducers of interferon γ , tumor necrosis factor (TNF), and other mediators play an important role in inducing a Th1 response. The mucosal inflammation of the small bowel in CD is also caused by Th1 activation, in response to dietary gluten. Previous studies showed that IL-18 is capable of promoting T cell interferon γ production and facilitating Th1 cell polarization (*Salvati et al., 2002*). These results are suggestive of interplay between skin, intestinal cells, and lymphocyte activation in unknown way.

AIM OF THE WORK

The aim of this study is to evaluate the prevalence of gluten sensitive enteropathy or coeliac disease in patients affected by psoriasis, by screening the antibodies of coeliac disease.

Patients and healthy controls will be screened for serum IgA antibodies to gliadin (AGA), IgA antitransglutaminase (TgA) as measured by ELISA and IgA antibodies to endomysium (EmA), assessed by standard immunofluorescence with cryosection of monkey esophagus.

PSORIASIS

Psoriasis is a chronic and debilitating inflammatory disease associated with serious co-morbidities and causes a significant impact on the patient's quality of life (*Gottlieb et al., 2008*).

1- **Epidemiology:**

a) **Incidence:**

Varieties of studies showed that psoriasis affects approximately 2-3% of the population worldwide (*Nickoloff and Nestle, 2004*). Other studies have estimated the prevalence of psoriasis to be 0.6% to 4.8% of the population. These estimations of the prevalence of psoriasis are variable based on Country studied, definition of prevalence used, method of psoriasis determination and sampling method used (*Stern et al., 2004; Gelfand et al., 2005*).

b) **Age:**

Psoriasis can begin at any age, although epidemiological studies showed that it mostly appears for the first time in between the age of 15 and 25 years. A study of the age of onset of psoriasis showed two peaks of onset, the first one from 16-22 years of age (early onset psoriasis) and the second from 57-60 years of age (late onset psoriasis). Males and females are equally affected with peak incidence of 22 years of age in males and 16 years of age in females, in case of early onset psoriasis (*Bowcock and Baker, 2003*).

c) **Sex:**

Psoriasis is not phenotypically different between both sexes (*Griffiths et al., 2004*) inspite of significant female preponderance in the palmoplantar pustular type and it is not social class linked (*Griffiths et al., 2000*).

d) Climate:

Climate appears to affect psoriasis prevalence, with higher rates recorded in single countries at greater latitudes from the equator (*Griffiths et al., 2004*). The symptoms of psoriasis improve in the summer and worsen in the winter for many patients (*Schón and Boehncke, 2005*). Climatotherapy, the simplest form which utilizes sunrays, has been used extensively at the Dead Sea (*Abels and Harari, 2000*) and at the red sea in Safaga (*El-Arabi, 2005*). Climatotherapy is a remittive therapy leading to a reversal of the immunopathologic abnormalities of psoriasis in involved epidermis and dermis (*Hodak et al., 2003; David et al., 2005*).

Definition of psoriasis severity:

Psoriasis is a chronic inflammatory skin condition that varies in severity. The Medical Advisory Board of the National Psoriasis Foundation published definitions of mild, moderate and severe psoriasis. These definitions are based largely on quality-of-life (QOL) measures, with consideration also given to proportion of body surface area affected as shown in *table 1* (*Krueger and Ellis, 2005*).